States Sue Trump Administration Over SNAP Restrictions for Legal Immigrants 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Mexico Probes Miss Universe President Raul Rocha Over Alleged Criminal Links 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Bolsonaro Blames Medication Mix-Up for Ankle Monitor Tampering as Detention Continues 
Northwestern University to Restore Research Funding Under $75 Million Agreement with U.S. Government 
Peru’s Ex-President Martín Vizcarra Sentenced to 14 Years in Prison for Corruption 
Trump Vows Pardon for Former Honduran President as Honduras Faces Tight Election 
Union Urges Court to Compel Trump Administration to Restore CFPB Funding 
Netanyahu Seeks Presidential Pardon Amid Ongoing Corruption Trial 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Singapore Court Allows $2.7 Billion 1MDB Lawsuit Against Standard Chartered to Proceed 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
